Teva Pharmaceutical Industries (TEVA) EBITDA (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly EBITDA came in at -$231.0 million in Q2 2026, down 150.77% YoY from $455.0 million in Q2 2025, and down 135.43% on a QoQ basis from $652.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) EBITDA (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of EBITDA data on file, last reported at -$231.0 million in Q2 2026.
- Quarterly EBITDA fell 150.77% year-over-year to -$231.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 79.31% YoY) and the FY2025 annual result came in at $2.2 billion, up 811.88% from the prior year.
- EBITDA declined to -$231.0 million in Q2 2026, from $652.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $882.0 million in Q3 2025 to a low of -$967.0 million in Q2 2022.
- A 5-year average of $28.4 million and a median of -$9.0 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA plunged 1576.92% — and 2025, when it surged 9200.0%.
- Tracing TEVA's EBITDA over 5 years: stood at -$940.0 million in 2022, then jumped by 180.43% to $756.0 million in 2023, then slumped by 103.84% to -$29.0 million in 2024, then jumped by 1134.48% to $300.0 million in 2025, then plunged by 177.0% to -$231.0 million in 2026.
- The last three EBITDA figures came in at -$231.0 million (Q2 2026), $652.0 million (Q1 2026), and $300.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn | 18.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -231.00 Mn |
| Mar 31, 2026 | 652.00 Mn |
| Dec 31, 2025 | 300.00 Mn |
| Sep 30, 2025 | 882.00 Mn |
| Jun 30, 2025 | 455.00 Mn |
| Mar 31, 2025 | 519.00 Mn |
| Dec 31, 2024 | -29.00 Mn |
| Sep 30, 2024 | -51.00 Mn |
| Jun 30, 2024 | -5.00 Mn |
| Mar 31, 2024 | -218.00 Mn |
| Dec 31, 2023 | 756.00 Mn |
| Sep 30, 2023 | 344.00 Mn |
| Jun 30, 2023 | -654.00 Mn |
| Mar 31, 2023 | -13.00 Mn |
| Dec 31, 2022 | -940.00 Mn |
| Sep 30, 2022 | 424.00 Mn |
| Jun 30, 2022 | -967.00 Mn |
| Mar 31, 2022 | -713.00 Mn |
| Dec 31, 2021 | 78.00 Mn |
| Sep 30, 2021 | 623.00 Mn |